Cellectis S.A. (CLLS) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NEW YORK, April 29, 2020 -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on.
Monthly information on share capital and company voting rights.
CLLS earnings call for the period ending March 31, 2020.
Cellectis S.A. (CLLS) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cellectis and Servier Execute the Amendment Confirming the Expansion of their Collaboration on UCART19 Products
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, May 12, 2020 -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal.
Cellectis S.A. (EPA:ALCLS) shareholders will doubtless be very grateful to see the share price up 47% in the last...
Proprietary allogeneic CAR T-cell programs on track in Phase 1 dose escalation trials; AMELI-01 in r/r AML patients, BALLI-01 in r/r B-ALL patients and MELANI-01 in r/r MM.
Cellectis S.A. (EPA:ALCLS) just released its quarterly report and things are looking bullish. The results were...
Cellectis has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
In the context of the COVID-19 epidemic and in accordance with Ordinance No. 2020-321 of March 25, 2020, the annual general meeting will take place on June 29, 2020 at 9 AM CET at Cellectis’ headquarters, located at 8, rue de la Croix Jarry, 4th floor, 75013 Paris, France behind closed doors, i.e. Under these conditions, shareholders are invited to vote remotely, prior to the General Meeting, by giving a proxy to the Chairman or by returning the voting form.
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced the appointment of Carrie Brownstein, M.D., to the role of Chief Medical Officer. In Dr. Brownstein’s new role, she will oversee clinical research and development for Cellectis’ UCART clinical trial programs. Dr. Brownstein joins Cellectis from Celgene, with a strong track record in hematology and myeloid diseases.
US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis
Cellectis (CLLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced the appointment of Leopold Bertea, Ph.D., to the role of Senior Vice President of Technical Operations - Europe. Dr. Bertea is based in the Cellectis Paris office and reports to Bill Monteith, Executive Vice President, Technical Operations.
Potential suitors looking to expand their work in cancer likely covet company's technology Continue reading...
Top Ranked Momentum Stocks to Buy for May 12th